Ajai Chari, MD, discusses the rationale for using combination therapy in patients with multiple myeloma.
Ajai Chari, MD, associate professor of medicine at the Mount Sinai School of Medicine, discusses the rationale for using combination therapy in patients with multiple myeloma.
Historically, Chari says that every drug in the treatment landscape has only worked for a short period of time in these patients. Because of this, the agents are combined to increase both response and duration of response, while also decreasing resistance.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
How BCMA CAR T-Cell Therapy Provides Later-Line Options in R/R Multiple Myeloma
May 10th 2024During a Case-Based Roundtable® event, Abdullah Khan, MBBS, discussed the different outcomes with idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma in both the clinic and real-world settings in the second article of a 2-part series.
Read More